Version 1
: Received: 13 December 2023 / Approved: 13 December 2023 / Online: 14 December 2023 (09:17:38 CET)
How to cite:
Ashoor, D.; Fathallah, M. In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86. Preprints2023, 2023121049. https://doi.org/10.20944/preprints202312.1049.v1
Ashoor, D.; Fathallah, M. In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86. Preprints 2023, 2023121049. https://doi.org/10.20944/preprints202312.1049.v1
Ashoor, D.; Fathallah, M. In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86. Preprints2023, 2023121049. https://doi.org/10.20944/preprints202312.1049.v1
APA Style
Ashoor, D., & Fathallah, M. (2023). In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86. Preprints. https://doi.org/10.20944/preprints202312.1049.v1
Chicago/Turabian Style
Ashoor, D. and M-Dahmani Fathallah. 2023 "In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86" Preprints. https://doi.org/10.20944/preprints202312.1049.v1
Abstract
The current globally dominant SARS-CoV-2 variants are showing immune escape and reduced susceptibility to antiviral drugs. Therefore, agencies responsible for drug evaluation and regula-tion such as the FDA and EMA are revising their emergency authorization use of several COVID-19 neutralizing antibodies. These NAbs proved to be unlikely effective against new variants espe-cially Omicron descendants and several pharmaceutical companies are pursuing the development of more potent neutralizing antibodies. To address the issue of using in silico prediction for the rapid assessment of anti-SARS-CoV-2 MAbs neutralization power, we used a computational method we developed previously, to evaluate 10 SARS-CoV-2 antibodies propensity to neutralize the new Omicron’s subvariants Eris (EG.5) and Pirola (BA.2.86) based on comparative binding affinity and previous experimental and clinical observations. Nine of these MAbs were once granted emergency use authorization, and one is currently under clinical investigation. The rapid, cost-effective in silico evaluation provided reliable predictions consistent with published clinical and experimental data. Furthermore, our data showed new potential therapeutic MAbs combi-nation that could be effective for the treatment countermeasure of the new Omicron’s subvariants Eris (EG.5) and Pirola (BA.2.86).
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
